Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis
New immunomodulatory drugs for the treatment of multiple sclerosis are emerging today in the pharmaceutical market. In Russia, new first line preparation - teriflunomide 14 mg in tablet form - was recently granted approval for the treatment of patients with remitting MS. The drug demonstrated good t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2015-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/455 |
| _version_ | 1797841718212558848 |
|---|---|
| author | N. Y. Lasch |
| author_facet | N. Y. Lasch |
| author_sort | N. Y. Lasch |
| collection | DOAJ |
| description | New immunomodulatory drugs for the treatment of multiple sclerosis are emerging today in the pharmaceutical market. In Russia, new first line preparation - teriflunomide 14 mg in tablet form - was recently granted approval for the treatment of patients with remitting MS. The drug demonstrated good tolerability, efficacy and relative safety in long-term clinical trials. The article discusses an algorithm for the management of patients with RMS aimed at reducing the risk of adverse events associated with teriflunomide therapy. |
| first_indexed | 2024-04-09T16:35:53Z |
| format | Article |
| id | doaj.art-b66caea5ad6b402bb8848d6c9ca410c1 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:35:53Z |
| publishDate | 2015-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-b66caea5ad6b402bb8848d6c9ca410c12023-04-23T06:56:55ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902015-12-01018636710.21518/2079-701X-2015-18-63-67455Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosisN. Y. Lasch0Neurosurgery and Medical Genetics of the Russian National Research Medical University named after N.I. PirogovNew immunomodulatory drugs for the treatment of multiple sclerosis are emerging today in the pharmaceutical market. In Russia, new first line preparation - teriflunomide 14 mg in tablet form - was recently granted approval for the treatment of patients with remitting MS. The drug demonstrated good tolerability, efficacy and relative safety in long-term clinical trials. The article discusses an algorithm for the management of patients with RMS aimed at reducing the risk of adverse events associated with teriflunomide therapy.https://www.med-sovet.pro/jour/article/view/455рассеянный склерозпрепаратыизменяющие течение рассеянного склерозатерифлуномидmultiple sclerosisteriflunomidemultiple sclerosis sease-modifying medications |
| spellingShingle | N. Y. Lasch Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis Медицинский совет рассеянный склероз препараты изменяющие течение рассеянного склероза терифлуномид multiple sclerosis teriflunomide multiple sclerosis sease-modifying medications |
| title | Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis |
| title_full | Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis |
| title_fullStr | Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis |
| title_full_unstemmed | Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis |
| title_short | Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis |
| title_sort | some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis |
| topic | рассеянный склероз препараты изменяющие течение рассеянного склероза терифлуномид multiple sclerosis teriflunomide multiple sclerosis sease-modifying medications |
| url | https://www.med-sovet.pro/jour/article/view/455 |
| work_keys_str_mv | AT nylasch someriskmanagementissuesinteriflunomidetreatmentofpatientswithremittingmultiplesclerosis |